Form 4: Cormorant Asset Management Reports Ownership Changes in Aardvark Therapeutics Following IPO

Cormorant Asset Management reports changes in beneficial ownership of Aardvark Therapeutics stock following the company's initial public offering.

Summary

• Cormorant Asset Management, LP, along with related entities and Bihua Chen, filed a Form 4 detailing changes in beneficial ownership of Aardvark Therapeutics, Inc. [AARD] common stock.
• On February 14, 2025, upon the closing of Aardvark Therapeutics' IPO, Series C Convertible Preferred Stock automatically converted into Common Stock at a 1-for-8.474 conversion ratio, resulting in 800,189 shares of Common Stock.
• This conversion ratio accounts for a reverse stock split effected by the Issuer on February 5, 2025.
• Cormorant acquired 800,189 shares of common stock through conversion and purchased 187,500 shares at $16 per share.
• Following these transactions, Cormorant's beneficial ownership includes 987,689 shares of Common Stock.
• The filing indicates that Cormorant Asset Management serves as the investment manager for Cormorant Global Healthcare Master Fund, LP and Cormorant Private Healthcare Fund V, LP.
• Bihua Chen serves as the managing member of the general partners of these funds.
• The reporting persons disclaim beneficial ownership of the shares except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It reflects expected transactions following an IPO.

Industry Context

Form 4 filings are standard practice following significant transactions like IPOs, providing transparency into ownership changes and insider activity. This filing indicates Cormorant Asset Management's continued involvement with Aardvark Therapeutics post-IPO.

Stakeholder Impact

• Shareholders: Provides transparency regarding ownership changes post-IPO.
• Potential Investors: Offers insights into institutional investor activity.

Key Dates